
X-linked Severe Combined Immunodeficiency (SCID) Market
Description
X-linked Severe Combined Immunodeficiency (SCID) Market Report and Forecast 2024-2032
The X-linked severe combined immunodeficiency (SCID) market is projected to grow at a CAGR of 4.1% during the forecast period of 2024-2032.
X-linked Severe Combined Immunodeficiency (SCID) Market Analysis
X-linked severe combined immunodeficiency (SCID) is a rare, inherited disorder caused by mutations in the IL2RG gene, severely affecting the immune system’s ability to combat infections. This results in the absence of functional T and NK cells, making patients highly susceptible to severe infections. Early treatment, usually through stem cell or bone marrow transplants, is essential for survival. Emerging gene therapy provide hope for longer-lasting treatment solutions.
Market Drivers
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
X-linked Severe Combined Immunodeficiency (SCID) Market Segmentation
Market Breakup by Indication
Market Breakup by Treatment
Market Breakup by Distributor
Market Breakup by Region
X-linked Severe Combined Immunodeficiency (SCID) Market Competitive Landscape
The competitive landscape of the X-linked SCID market features major pharmaceutical and biotech companies. GSK Plc, Jasper Therapeutics, Inc., Graphite Bio, Inc., and Sangamo Therapeutics, Inc. are some of the leading players developing advanced gene therapies and transplant solutions. Merck & Co., Inc., Myriad Genetics, Inc., and Intellia Therapeutics, Inc. are also making significant strides, particularly in diagnostics and personalised treatments. Collaborative efforts among these companies are shaping the future of SCID treatments.
Key Questions Answered in the Report
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the X-linked severe combined immunodeficiency (SCID) market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the X-linked severe combined immunodeficiency (SCID) market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the X-linked severe combined immunodeficiency (SCID) industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The X-linked severe combined immunodeficiency (SCID) market is projected to grow at a CAGR of 4.1% during the forecast period of 2024-2032.
X-linked Severe Combined Immunodeficiency (SCID) Market Analysis
X-linked severe combined immunodeficiency (SCID) is a rare, inherited disorder caused by mutations in the IL2RG gene, severely affecting the immune system’s ability to combat infections. This results in the absence of functional T and NK cells, making patients highly susceptible to severe infections. Early treatment, usually through stem cell or bone marrow transplants, is essential for survival. Emerging gene therapy provide hope for longer-lasting treatment solutions.
Market Drivers
- Advancements in Gene Therapy: Continued progress in gene therapy offers curative potential for X-linked SCID, enhancing treatment outcomes by addressing the genetic root of the disease. This innovation is expected to fuel market growth as more therapies receive regulatory approval and are commercialised.
- Newborn Screening Initiatives: The increasing implementation of newborn screening programs globally helps in early detection and treatment of SCID, improving patient survival rates and driving demand for advanced therapies.
- Rising Awareness of Rare Diseases: Enhanced public awareness and advocacy for rare diseases, including SCID, contribute to early diagnosis and drive demand for innovative treatment solutions, further pushing the market forward.
- Innovations in Stem Cell Transplantation: Technological advancements in stem cell transplantation have improved success rates, making this procedure a viable option for curing SCID. This development is driving growth in the SCID treatment market.
- Growing Healthcare Investment: Increased funding for healthcare and research, especially in developed regions, is enabling the development of advanced SCID treatments, including gene therapies and new medications, driving overall market expansion.
- Limited Donor Availability: Finding compatible donors for bone marrow and stem cell transplants is challenging, particularly for patients from ethnic minority groups, affecting the success of treatment for SCID.
- Regulatory Hurdles: Strict regulatory requirements for gene therapies and other novel treatments can delay the approval process, limiting the availability of new treatment options for SCID patients.
- Potential Complications from Transplants: Stem cell and bone marrow transplants carry risks of complications such as graft-versus-host disease, which can impact treatment success and patient outcomes.
- Lack of Awareness in Low-Income Regions: In developing countries, awareness of X-linked SCID and its treatments is low, leading to delayed diagnosis and treatment, which can hinder market growth in these regions.
- Expansion of Genetic Screening Programs: The global expansion of newborn genetic screening programs for early diagnosis of SCID presents significant growth opportunities, enabling more timely interventions and improving patient outcomes.
- Advancements in Personalised Medicine: Personalised gene therapy tailored to individual patients offers the potential for more effective treatments, creating opportunities for biotech companies to develop targeted solutions for SCID.
- Rising Demand for Telemedicine: The increasing use of telemedicine offers opportunities to expand access to SCID diagnosis and treatment, particularly in remote and underserved areas, improving patient care and market reach.
- Collaboration for Research and Development: Partnerships between pharmaceutical companies, biotech firms, and research institutions could accelerate the development of innovative SCID treatments, driving market growth.
- Increased Focus on Rare Disease Research: Growing attention to rare diseases, driven by advocacy groups and governments, is boosting funding for research into SCID treatments, providing opportunities for new therapies and solutions.
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Expansion of Gene Therapy
- Growth in Newborn Screening
- Increased Collaboration Between Biotech Firms
- Rising Demand for Advanced Diagnostic Tools
- Focus on Minimising Transplant Complications
- Expansion of Telemedicine
X-linked Severe Combined Immunodeficiency (SCID) Market Segmentation
Market Breakup by Indication
- il2rg SCID
- Common Gamma Chain SCID
Market Breakup by Treatment
- Surgery
- Stem Cell Transplant
- Bone Marrow Transplant
- Medication
- Gene Therapy
Market Breakup by Distributor
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
X-linked Severe Combined Immunodeficiency (SCID) Market Competitive Landscape
The competitive landscape of the X-linked SCID market features major pharmaceutical and biotech companies. GSK Plc, Jasper Therapeutics, Inc., Graphite Bio, Inc., and Sangamo Therapeutics, Inc. are some of the leading players developing advanced gene therapies and transplant solutions. Merck & Co., Inc., Myriad Genetics, Inc., and Intellia Therapeutics, Inc. are also making significant strides, particularly in diagnostics and personalised treatments. Collaborative efforts among these companies are shaping the future of SCID treatments.
Key Questions Answered in the Report
- What are the driving factors for the growth of the X-linked SCID market?
- How are gene therapies shaping the future of X-linked SCID treatment?
- What challenges do companies face in delivering effective SCID treatments globally?
- How is the market segmented based on treatment types, and which segment dominates?
- What role do emerging markets play in the expansion of SCID treatment access?
- What are the trends in gene and stem cell therapy for treating SCID?
- How is telemedicine contributing to SCID patient care?
- How do regulatory frameworks affect the approval of new SCID therapies?
- Which key players are leading the innovation in X-linked SCID treatments?
- How do newborn screening programs impact the early diagnosis of X-linked SCID?
- What are the regional differences in the availability of SCID treatments?
- What opportunities exist for new market entrants in the X-linked SCID market?
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the X-linked severe combined immunodeficiency (SCID) market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the X-linked severe combined immunodeficiency (SCID) market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the X-linked severe combined immunodeficiency (SCID) industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 X-Linked Severe Combined Immunodeficiency SCID Market Overview – 8 Major Markets
- 3.1 X-Linked Severe Combined Immunodeficiency SCID Market Historical Value (2018-2024)
- 3.2 X-Linked Severe Combined Immunodeficiency SCID Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 X-Linked Severe Combined Immunodeficiency SCID Market Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Type
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 X-Linked Severe Combined Immunodeficiency SCID Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 X-Linked Severe Combined Immunodeficiency SCID Market Landscape – 8 Major Markets
- 8.1 X-Linked Severe Combined Immunodeficiency SCID Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 X-Linked Severe Combined Immunodeficiency SCID Market: Product Landscape
- 8.2.1 Analysis by Indication
- 8.2.2 Analysis by Treatment
- 9 X-Linked Severe Combined Immunodeficiency SCID Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 X-Linked Severe Combined Immunodeficiency SCID Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 X-Linked Severe Combined Immunodeficiency SCID Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Indication
- 12.1.1 Market Overview
- 12.1.2 il2rg SCID
- 12.1.3 Common Gamma Chain SCID
- 12.2 X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Treatment
- 12.2.1 Market Overview
- 12.2.2 Surgery
- 12.2.2.1 Stem Cell Transplant
- 12.2.2.2 Bone Marrow Transplant
- 12.2.3 Medication
- 12.2.4 Gene Therapy
- 12.3 X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Distributor
- 12.3.1 Market Overview
- 12.3.2 Hospital Pharmacy
- 12.3.3 Retail Pharmacy
- 12.3.4 Online Pharmacies
- 12.3.5 Others
- 12.4 X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Country
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 United Kingdom
- 12.4.4 Germany
- 12.4.5 France
- 12.4.6 Italy
- 12.4.7 Spain
- 12.4.8 Japan
- 12.4.9 India
- 13 United States X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034)
- 13.1 United States X-Linked Severe Combined Immunodeficiency SCID Market Historical Value (2018-2024)
- 13.2 United States X-Linked Severe Combined Immunodeficiency SCID Market Forecast Value (2025-2034)
- 13.3 United States X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Indication
- 13.3.1 Market Overview
- 13.3.2 il2rg SCID
- 13.3.3 Common Gamma Chain SCID
- 13.4 United States X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Treatment
- 13.4.1 Market Overview
- 13.4.2 Surgery
- 13.4.2.1 Stem Cell Transplant
- 13.4.2.2 Bone Marrow Transplant
- 13.4.3 Medication
- 13.4.4 Gene Therapy
- 13.5 United States X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Distributor
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacy
- 13.5.3 Retail Pharmacy
- 13.5.4 Online Pharmacies
- 13.5.5 Others
- 14 United Kingdom X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034)
- 14.1 United Kingdom X-Linked Severe Combined Immunodeficiency SCID Market Historical Value (2018-2024)
- 14.2 United Kingdom X-Linked Severe Combined Immunodeficiency SCID Market Forecast Value (2025-2034)
- 14.3 United Kingdom X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Indication
- 14.3.1 Market Overview
- 14.3.2 il2rg SCID
- 14.3.3 Common Gamma Chain SCID
- 14.4 United Kingdom X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Treatment
- 14.4.1 Market Overview
- 14.4.2 Surgery
- 14.4.2.1 Stem Cell Transplant
- 14.4.2.2 Bone Marrow Transplant
- 14.4.3 Medication
- 14.4.4 Gene Therapy
- 14.5 United Kingdom X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Distributor
- 14.5.1 Market Overview
- 14.5.2 Hospital Pharmacy
- 14.5.3 Retail Pharmacy
- 14.5.4 Online Pharmacies
- 14.5.5 Others
- 15 France X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034)
- 15.1 France X-Linked Severe Combined Immunodeficiency SCID Market Historical Value (2018-2024)
- 15.2 France X-Linked Severe Combined Immunodeficiency SCID Market Forecast Value (2025-2034)
- 15.3 France X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Indication
- 15.3.1 Market Overview
- 15.3.2 il2rg SCID
- 15.3.3 Common Gamma Chain SCID
- 15.4 France X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Treatment
- 15.4.1 Market Overview
- 15.4.2 Surgery
- 15.4.2.1 Stem Cell Transplant
- 15.4.2.2 Bone Marrow Transplant
- 15.4.3 Medication
- 15.4.4 Gene Therapy
- 15.5 France X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Distributor
- 15.5.1 Market Overview
- 15.5.2 Hospital Pharmacy
- 15.5.3 Retail Pharmacy
- 15.5.4 Online Pharmacies
- 15.5.5 Others
- 16 Italy X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034)
- 16.1 Italy X-Linked Severe Combined Immunodeficiency SCID Market Historical Value (2018-2024)
- 16.2 Italy X-Linked Severe Combined Immunodeficiency SCID Market Forecast Value (2025-2034)
- 16.3 Italy X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Indication
- 16.3.1 Market Overview
- 16.3.2 il2rg SCID
- 16.3.3 Common Gamma Chain SCID
- 16.4 Italy X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Treatment
- 16.4.1 Market Overview
- 16.4.2 Surgery
- 16.4.2.1 Stem Cell Transplant
- 16.4.2.2 Bone Marrow Transplant
- 16.4.3 Medication
- 16.4.4 Gene Therapy
- 16.5 Italy X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Distributor
- 16.5.1 Market Overview
- 16.5.2 Hospital Pharmacy
- 16.5.3 Retail Pharmacy
- 16.5.4 Online Pharmacies
- 16.5.5 Others
- 17 Spain X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034)
- 17.1 Spain X-Linked Severe Combined Immunodeficiency SCID Market Historical Value (2018-2024)
- 17.2 Spain X-Linked Severe Combined Immunodeficiency SCID Market Forecast Value (2025-2034)
- 17.3 Spain X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Indication
- 17.3.1 Market Overview
- 17.3.2 il2rg SCID
- 17.3.3 Common Gamma Chain SCID
- 17.4 Spain X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Treatment
- 17.4.1 Market Overview
- 17.4.2 Surgery
- 17.4.2.1 Stem Cell Transplant
- 17.4.2.2 Bone Marrow Transplant
- 17.4.3 Medication
- 17.4.4 Gene Therapy
- 17.5 Spain X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Distributor
- 17.5.1 Market Overview
- 17.5.2 Hospital Pharmacy
- 17.5.3 Retail Pharmacy
- 17.5.4 Online Pharmacies
- 17.5.5 Others
- 18 Japan X-Linked Severe Combined Immunodeficiency SCID Market
- 18.1 Japan X-Linked Severe Combined Immunodeficiency SCID Market Historical Value (2018-2024)
- 18.2 Japan X-Linked Severe Combined Immunodeficiency SCID Market Forecast Value (2025-2034)
- 18.3 Japan X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Indication
- 18.3.1 Market Overview
- 18.3.2 il2rg SCID
- 18.3.3 Common Gamma Chain SCID
- 18.4 Japan X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Treatment
- 18.4.1 Market Overview
- 18.4.2 Surgery
- 18.4.2.1 Stem Cell Transplant
- 18.4.2.2 Bone Marrow Transplant
- 18.4.3 Medication
- 18.4.4 Gene Therapy
- 18.5 Japan X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Distributor
- 18.5.1 Market Overview
- 18.5.2 Hospital Pharmacy
- 18.5.3 Retail Pharmacy
- 18.5.4 Online Pharmacies
- 18.5.5 Others
- 19 India X-Linked Severe Combined Immunodeficiency SCID Market
- 19.1 India X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) Historical Value (2018-2024)
- 19.2 India X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) Forecast Value (2025-2034)
- 19.3 India X-Linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Indication
- 19.3.1 Market Overview
- 19.3.2 il2rg SCID
- 19.3.3 Common Gamma Chain SCID
- 19.4 India X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Treatment
- 19.4.1 Market Overview
- 19.4.2 Surgery
- 19.4.2.1 Stem Cell Transplant
- 19.4.2.2 Bone Marrow Transplant
- 19.4.3 Medication
- 19.4.4 Gene Therapy
- 19.5 India X-linked Severe Combined Immunodeficiency SCID Market (2018-2034) by Distributor
- 19.5.1 Market Overview
- 19.5.2 Hospital Pharmacy
- 19.5.3 Retail Pharmacy
- 19.5.4 Online Pharmacies
- 19.5.5 Others
- 20 Regulatory Framework
- 20.1 Regulatory Overview
- 20.2 US FDA
- 20.3 EU EMA
- 20.4 Japan PMDA
- 20.5 India CDSCO
- 20.6 Others
- 21 Patent Analysis
- 21.1 Analysis by Treatment of Patent
- 21.2 Analysis by Publication Year
- 21.3 Analysis by Issuing Authority
- 21.4 Analysis by Patent Age
- 21.5 Analysis by CPC Analysis
- 21.6 Analysis by Patent Valuation
- 21.7 Analysis by Key Players
- 22 Clinical Trials and Pipeline Analysis
- 22.1 Analysis by Trial Registration Year
- 22.2 Analysis by Trial Status
- 22.3 Analysis by Trial Phase
- 22.4 Analysis by Therapeutic Area
- 22.5 Analysis by Geography
- 22.6 Treatment Pipeline Assessment
- 23 Grants Analysis
- 23.1 Analysis by Year
- 23.2 Analysis by Amount Awarded
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Grant Application
- 23.5 Analysis by Funding Institute
- 23.6 Analysis by NIH Departments
- 23.7 Analysis by Recipient Organization
- 24 Funding and Investment Analysis
- 24.1 Analysis by Funding Instances
- 24.2 Analysis by Treatment of Funding
- 24.3 Analysis by Funding Amount
- 24.4 Analysis by Leading Players
- 24.5 Analysis by Leading Investors
- 24.6 Analysis by Geography
- 25 Strategic Initiatives
- 25.1 Analysis by Partnership Instances
- 25.2 Analysis by Treatment of Partnership
- 25.3 Analysis by Leading Players
- 25.4 Analysis by Geography
- 26 Supplier Landscape
- 26.1 Market Share by Top 5 Companies
- 26.2 GSK Plc
- 26.2.1 Financial Analysis
- 26.2.2 Product Portfolio
- 26.2.3 Demographic Reach and Achievements
- 26.2.4 Companies News and Developments
- 26.2.5 Certifications
- 26.3 Jasper Therapeutics, Inc.
- 26.3.1 Financial Analysis
- 26.3.2 Product Portfolio
- 26.3.3 Demographic Reach and Achievements
- 26.3.4 Companies News and Developments
- 26.3.5 Certifications
- 26.4 Graphite Bio, Inc.
- 26.4.1 Financial Analysis
- 26.4.2 Product Portfolio
- 26.4.3 Demographic Reach and Achievements
- 26.4.4 Companies News and Developments
- 26.4.5 Certifications
- 26.5 Merck & Co., Inc.
- 26.5.1 Financial Analysis
- 26.5.2 Product Portfolio
- 26.5.3 Demographic Reach and Achievements
- 26.5.4 Companies News and Developments
- 26.5.5 Certifications
- 26.6 Myriad Genetics, Inc.
- 26.6.1 Financial Analysis
- 26.6.2 Product Portfolio
- 26.6.3 Demographic Reach and Achievements
- 26.6.4 Companies News and Developments
- 26.6.5 Certifications
- 26.7 Sangamo Therapeutics, Inc
- 26.7.1 Financial Analysis
- 26.7.2 Product Portfolio
- 26.7.3 Demographic Reach and Achievements
- 26.7.4 Companies News and Developments
- 26.7.5 Certifications
- 26.8 Intellia Therapeutics, Inc.
- 26.8.1 Financial Analysis
- 26.8.2 Product Portfolio
- 26.8.3 Demographic Reach and Achievements
- 26.8.4 Companies News and Developments
- 26.8.5 Certifications
- 27 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.